Bioenergetic approaches for neuroprotection in Parkinson's disease

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777

Mitochondrial Complex I Deficiency in Parkinson's Disease

Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283

Superoxide activates mitochondrial uncoupling proteins

Echtay, K. S., Roussel, D., St-Pierre, J., Jekabsons, M. B., Cadenas, S., Stuart, J. A., Harper, J. A., Roebuck, S. J., Morrison, A., Pickering, S., et al. (2002) · Nature · doi:10.1038/415096a · Cited by 1,382

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

Nicklas, W. J., Vyas, I. L., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,273

Generation of reactive oxygen species by the mitochondrial electron transport chain

Liu, Y., Fiskum, G., & Schubert, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00744.x · Cited by 1,260

Abnormalities of the electron transport chain in idiopathic parkinson's disease

Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061

A Fraction of Yeast Cu,Zn-Superoxide Dismutase and Its Metallochaperone, CCS, Localize to the Intermembrane Space of Mitochondria

Sturtz, L. A., Diekert, K., Jensen, L. T., Lill, R., & Culotta, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105296200 · Cited by 735

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

Gorell, J., Johnson, C. C., Rybicki, B., Peterson, E., & Richardson, R. (1998) · Neurology · doi:10.1212/wnl.50.5.1346 · Cited by 694

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis

Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682

Experimental models of Parkinson's disease

Beal, M. F. (2001) · Nature reviews. Neuroscience · doi:10.1038/35072550 · Cited by 645

The Role of Oxidative Stress in Parkinson's Disease

Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845

Mitochondria in neuroplasticity and neurological disorders

Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow, C. W., Stern, M. B., & Sethi, K. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 947

Bioenergetics and the formation of mitochondrial reactive oxygen species

Ádám‐Vizi, V., & Chinopoulos, C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.005 · Cited by 623

Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research

Stork, C., & Renshaw, P. F. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001711 · Cited by 489

Acylcarnitines: Role in brain

Jones, L. L., McDonald, D. A., & Borum, P. R. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.08.004 · Cited by 459

Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases

Mandel, S. A., & Youdim, M. B. H. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.04.012 · Cited by 453

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426

Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases

Mandel, S. A., Weinreb, O., Amit, T., & Youdim, M. B. H. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02291.x · Cited by 384

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)

Singh, N. A., Mandal, A. K. A., & Khan, Z. A. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0179-4 · Cited by 324

Redox imbalance in Parkinson's disease

Chinta, S. J., & Andersen, J. K. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.02.005 · Cited by 303

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294

Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis -An updated review

Alqahtani, T., Deore, S. L., Kide, A. A., Shende, B. A., Sharma, R., Chakole, R. D., Nemade, L. S., Kale, N. K., Borah, S., Deokar, S. S., et al. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.05.007 · Cited by 302

The Effects and Mechanisms of Mitochondrial Nutrient α-Lipoic Acid on Improving Age-Associated Mitochondrial and Cognitive Dysfunction: An Overview

Liu, J. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9403-0 · Cited by 268

Neurodegeneration and neuroprotection in Parkinson disease

Fahn, S., & Sulzer, D. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 275

Disease‐modifying strategies for Parkinson's disease

Kalia, L. V., Kalia, S. K., & Lang, A. E. (2015) · Movement Disorders · doi:10.1002/mds.26354 · Cited by 254

Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation

Wang, J.-Y., Wen, L. L., Huang, Y.-N., Chen, Y.-T., & Ku, M.-C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778343109 · Cited by 250

l-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders

Ribas, G. S., Vargas, C. R., & Wajner, M. (2013) · Gene · doi:10.1016/j.gene.2013.10.017 · Cited by 247

Neuroprotective Strategies in Parkinson???s Disease

Mandel, S. A., Grünblatt, E., Riederer, P. F., Gerlach, M., Levites, Y., & Youdim, M. B. H. (2003) · CNS Drugs · doi:10.2165/00023210-200317100-00004 · Cited by 240

Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?

Harrison, I. F., & Dexter, D. T. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.010 · Cited by 233

Redox imbalance

Berg, D., Youdim, M. B. H., & Riederer, P. F. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 221

Benefits of curcumin in brain disorders

Bhat, A., Mahalakshmi, A. M., Ray, B., Tuladhar, S., Hediyal, T. A., Manthiannem, E., Jagadeeswari, P., Chandra, R., Chidambaram, S. B., & Sakharkar, M. K. (2019) · BioFactors · doi:10.1002/biof.1533 · Cited by 208

Progress in Parkinson's disease—Where do we stand?

Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197

Discovery and Validation of Plasma Biomarkers for Major Depressive Disorder Classification Based on Liquid Chromatography–Mass Spectrometry

Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., Zhao, J., Zhou, J., Xie, P., & Xu, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00144 · Cited by 193

Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress

Wolf, A. M., Asoh, S., Hiranuma, H., Ohsawa, I., Iio, K., Satou, A., Ishikura, M., & Ohta, S. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.01.011 · Cited by 191

Luminescent Lanthanides in Biorelated Applications: From Molecules to Nanoparticles and Diagnostic Probes to Therapeutics

Alexander, C., Guo, Z., Glover, P. B., Faulkner, S., & Pikramenou, Z. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00615 · Cited by 203

Coenzyme Q10 effects in neurodegenerative disease

Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 189

Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases

Adhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 190

Advances in anion binding and sensing using luminescent lanthanide complexes

Bodman, S. E., & Butler, S. J. (2021) · Chemical Science · doi:10.1039/d0sc05419d · Cited by 179

Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: Involvement of the transcription factor Nrf2

Calabrese, V., Ravagna, A., Colombrita, C., Scapagnini, G., Guagliano, E., Calvani, M., Butterfield, D. A., & Stella, A. M. G. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20386 · Cited by 170

The mitochondrial permeability transition in neurologic disease

Norenberg, M. D., & RAO, K. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.02.008 · Cited by 168

The mitochondrial free radical theory of ageing - Where do we stand?

Gruber, J. (2008) · Frontiers in bioscience · doi:10.2741/3174 · Cited by 171

Role of carnitine esters in brain neuropathology

Virmani, A. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.003 · Cited by 169

Neuroprotection in glaucoma – Is there a future role?

Baltmr, A., Duggan, J., Nizari, S., Salt, T. E., & Cordeiro, M. F. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.009 · Cited by 156

Mitochondria as ATP consumers in cellular pathology

Chinopoulos, C., & Ádám‐Vizi, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.008 · Cited by 147

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 164

Polyhydroxylated fullerene derivative C60(OH)24 prevents mitochondrial dysfunction and oxidative damage in an MPP+‐induced cellular model of Parkinson's disease

Cai, X., Jia, H., Liu, Z., Hou, B., Luo, C. Y., Feng, Z., Li, W., & Liu, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21805 · Cited by 150

The role of mitochondria in neurodegenerative diseases

Filosto, M., Scarpelli, M., Cotelli, M. S., Vielmi, V., Todeschini, A., Gregorelli, V., Tonin, P., Tomelleri, G., & Padovani, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6104-z · Cited by 142

Mitochondria and Neurodegeneration

Petrozzi, L., Ricci, G., Giglioli, N. J., Siciliano, G., & Mancuso, M. (2007) · Bioscience Reports · doi:10.1007/s10540-007-9038-z · Cited by 139

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139

Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease

Liu, J., & Ames, B. N. (2005) · Nutritional Neuroscience · doi:10.1080/10284150500047161 · Cited by 138

Broken or maladaptive? Altered trajectories in neuroinflammation and behavior after early life adversity

Ganguly, P., & Brenhouse, H. C. (2015) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2014.07.001 · Cited by 136

Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases

Shadfar, S., Parakh, S., Jamali, M. S., & Atkin, J. D. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00350-4 · Cited by 148

Acrolein is a mitochondrial toxin: Effects on respiratory function and enzyme activities in isolated rat liver mitochondria

Sun, L., Luo, C. Y., Long, J., Wei, D., & Liu, J. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.04.003 · Cited by 128

Protective Effect of Carnosine During Nitrosative Stress in Astroglial Cell Cultures

Calabrese, V., Colombrita, C., Guagliano, E., Sapienza, M. A., Ravagna, A., Cardile, V., Scapagnini, G., Santoro, A. M., Mangiameli, A., Butterfield, D. A., et al. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6874-8 · Cited by 119

Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water-soluble formulation of Coenzyme Q10

Somayajulu‐Nitu, M., Sandhu, J. K., Cohen, J. S., Sikorska, M., Sridhar, T., Matei, A., Borowy‐Borowski, H., & Pandey, S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-88 · Cited by 117

Antioxidative Effect of Vitamin D3 on Zinc-Induced Oxidative Stress in CNS

Lin, A. M.-Y., CHEN, K. B., & CHAO, P. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1344.028 · Cited by 113

The neurobiology of acetyl-L-carnitine

Traina, G. (2016) · Frontiers in bioscience · doi:10.2741/4459 · Cited by 115

Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management.

Kidd, P. M. (2005) · PubMed · Cited by 104

Mitochondrial Dysfunction and Oxidative Stress in Parkinson’s Disease

Onyango, I. G. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9482-y · Cited by 100

Development of Mitochondria‐targeted Aromatic‐cationic Peptides for Neurodegenerative Diseases

Szeto, H. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.013 · Cited by 100

MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases

Catanesi, M., d’Angelo, M., Tupone, M. G., Benedetti, E., Giordano, A., Castelli, V., & Cimini, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175986 · Cited by 101

Coenzyme Q10:A Review of Its Promise as a Neuroprotectant

Young, A. J., Johnson, S., Steffens, D. C., & Doraiswamy, P. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900020538 · Cited by 100

Physical activity and COVID-19. The basis for an efficient intervention in times of COVID-19 pandemic

Clemente‐Suárez, V. J., Beltrán-Velasco, A. I., Ramos‐Campo, D. J., Mielgo‐Ayuso, J., Nikolaidis, P. Τ., Belando‐Pedreño, N., & Tornero-Aguilera, J. F. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113667 · Cited by 107

Treatment strategies for Parkinson’s disease

Yuan, H., Zhang, Z., Liang, L.-W., Shen, Q., Wang, X.-D., Ren, S.-M., Ma, H., Jiao, S.-J., & Liu, P. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-0302-z · Cited by 96

High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease

Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., Jia, X., Zhang, H., & Liu, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21650 · Cited by 98

Creatine Supplementation Normalizes Mutagenesis of Mitochondrial DNA as Well as Functional Consequences

Berneburg, M., Gremmel, T., Kürten, V., Schröeder, P., Hertel, I., von Mikecz, A. H., Wild, S., Chen, M., Declercq, L., Matsui, M. S., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23806.x · Cited by 94

Current perspective of mitochondrial biology in Parkinson's disease

Kaidery, N. A., & Thomas, B. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.001 · Cited by 95

Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain

Alves, E. A., BINIENDA, Z. K., Carvalho, F. D., Alves, C. J., Fernandes, E. G. R., Bastos, M. D. L., Tavares, M. A., & Summavielle, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.041 · Cited by 91

Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders

McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.01.013 · Cited by 87

Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration

Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 89

Combined R‐α–lipoic acid and acetyl‐L‐carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease

Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., Wang, X., Li, X., Luo, C. Y., & Liu, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00390.x · Cited by 88

Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria?

Bogaerts, V., Theuns, J., & Broeckhoven, C. V. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 91

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

Schifitto, G., Zhang, J., Evans, S. R., Sacktor, N. C., Simpson, D. M., Millar, L., Hung, V., Miller, E. N., Smith, E. V., Ellis, R. J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000268487.78753.0f · Cited by 86

Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection

Mounsey, R. B., & Teismann, P. (2010) · Parkinson s Disease · doi:10.4061/2011/617472 · Cited by 86

Mitochondrial medicine for neurodegenerative diseases

Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82

Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells

Esposito, E., Iacono, A., Muià, C., Crisafulli, C., Raso, G. M., Bramanti, P., Meli, R., & Cuzzocrea, S. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00492.x · Cited by 81

Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration

Molz, P., & Schröder, N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00849 · Cited by 83

Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders

Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 85

Distinct Mechanisms of Neurodegeneration Induced by Chronic Complex I Inhibition in Dopaminergic and Non-dopaminergic Cells

Kweon, G., Marks, J. D., Krencik, R., Leung, E. H., Schumacker, P. T., Hyland, Κ., & Kang, U. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407336200 · Cited by 77

ATPase Activity of p97/Valosin-containing Protein Is Regulated by Oxidative Modification of the Evolutionally Conserved Cysteine 522 Residue in Walker A Motif

Noguchi, M., Takata, T., Kimura, Y., Manno, A., Murakami, K., Koike, M., Ohizumi, H., Hori, S., & Kakizuka, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509700200 · Cited by 74

Redox Modulation of Heat Shock Protein Expression by Acetylcarnitine in Aging Brain: Relationship to Antioxidant Status and Mitochondrial Function

Calabrese, V., Colombrita, C., Rukhsana Sultana, A., Scapagnini, G., Calvani, M., Butterfield, D. A., & Stella, A. M. G. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.404 · Cited by 69

Disease modification in Parkinson's disease

Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 67

Autotoxicity, methylation and a road to the prevention of Parkinson’s disease

Williams, A. C., & Ramsden, D. B. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.10.002 · Cited by 65

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

Gibrat, C., & Cicchetti, F. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.023 · Cited by 68

Neuroprotective effects of coenzyme Q10 on neurological diseases: a review article

Bagheri, S., Haddadi, R., Saki, S., Kourosh‐Arami, M., Rashno, M., Mojaver, A., & Komaki‬, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1188839 · Cited by 74

Effects of Metabolic Modifiers Such as Carnitines, Coenzyme Q10, and PUFAs against Different Forms of Neurotoxic Insults: Metabolic Inhibitors, MPTP, and Methamphetamine

Virmani, A., Gaetani, F., & BINIENDA, Z. K. (2005) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2005.tb00024.x · Cited by 65

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease

Jenner, P. G. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s13 · Cited by 64

Clinical trials of coenzyme Q10 in neurological disorders

Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62

Mitochondrial therapies for Parkinson's disease

Thomas, B., & Beal, M. F. (2010) · Movement Disorders · doi:10.1002/mds.22781 · Cited by 62

Nicotinamide: A double edged sword

Williams, A. C., & Ramsden, D. B. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.05.011 · Cited by 61

The ketogenic diet in a pill: Is this possible?

Rho, J. M., & Sankar, R. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01857.x · Cited by 61

Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy

Olanow, C. W., & Jankovic, J. J. (2005) · Movement Disorders · doi:10.1002/mds.20457 · Cited by 61

Broad neuroprotective profile of nicotinamide in different mouse models of MPTP‐induced parkinsonism

Anderson, D. W., Bradbury, K. A., & Schneider, J. S. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06356.x · Cited by 60

Alterations in bioenergetic function induced by Parkinson’s disease mimetic compounds: lack of correlation with superoxide generation

Dranka, B. P., Zielonka, J., Kanthasamy, A. G., & Kalyanaraman, B. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07836.x · Cited by 59

The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease

Harrison, I. F., Powell, N. M., & Dexter, D. T. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14599 · Cited by 59

Mechanism study of Aconitum-induced neurotoxicity in PC12 cells: Involvement of dopamine release and oxidative damage

Zhao, Y., Bu, Q., Zhou, Y. N., Lv, L., Yan, G., Chen, B., Wang, L., & Cen, X. (2010) · NeuroToxicology · doi:10.1016/j.neuro.2010.06.005 · Cited by 57

The Neuroprotective Role of Creatine

Klein, A., & Ferrante, R. J. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6486-9_11 · Cited by 56

Acetyl-l-carnitine reduces impulsive behaviour in adolescent rats

Adriani, W., Rea, M., Baviera, M., Invernizzi, R. W., Carli, M., Ghirardi, O., Caprioli, A., & Laviola, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1892-9 · Cited by 58

Mitochondrial Reactive Oxygen Species Inactivate Neuronal Nicotinic Acetylcholine Receptors and Induce Long-Term Depression of Fast Nicotinic Synaptic Transmission

Campanucci, V. A., Krishnaswamy, A., & Cooper, E. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5130-07.2008 · Cited by 55

Neuroprotective Therapy in Parkinson Disease

Chen, S., & Le, W. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000174353.28012.a7 · Cited by 53

Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease

Stack, E. C., Ferro, J. L., Kim, J.-H., Signore, S. J. D., Goodrich, S., Matson, S. A., Hunt, B. B., Cormier, K., Smith, K., Matson, W. R., et al. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.006 · Cited by 53

Parkinson's disease: the first common neurological disease due to auto-intoxication?

Williams, A. C., Cartwright, L. S., & Ramsden, D. B. (2005) · QJM · doi:10.1093/qjmed/hci027 · Cited by 53

Real-Time Monitoring of Oxidative Stress in Live Mouse Skin

Wolf, A. M., Nishimaki, K., Kamimura, N., & Ohta, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.428 · Cited by 54

Protective Effects of Coenzyme Q10 Against Hydrogen Peroxide-Induced Oxidative Stress in PC12 Cell: The Role of Nrf2 and Antioxidant Enzymes

Li, L., Du, J., Lian, Y., Zhang, Y. L., Li, X., Liu, Y., Zou, L., & Wu, T. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0224-4 · Cited by 51

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

Schapira, A. H. V., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10514 · Cited by 50

Protective effect of verbascoside in activated C6 glioma cells: possible molecular mechanisms

Esposito, E., Toso, R. D., Pressi, G., Bramanti, P., Meli, R., & Cuzzocrea, S. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0466-0 · Cited by 49

Role of Combined Lipoic Acid and Vitamin D3 on Astrocytes as a Way to Prevent Brain Ageing by Induced Oxidative Stress and Iron Accumulation

Molinari, C. G., Morsanuto, V., Ghirlanda, S., Ruga, S., Notte, F., Gaetano, L., & Uberti, F. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2843121 · Cited by 50

Effects of Astaxanthin Supplementation on Oxidative Stress

Wu, D., Xu, H. Y., Chen, J., & Zhang, L. (2019) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000497 · Cited by 50

Natural compounds: evidence for a protective role in eye disease

Ritch, R. H. (2007) · Canadian Journal of Ophthalmology · doi:10.3129/can.j.ophthalmol.i07-044 · Cited by 46

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 104

Mitochondria: Prospective Targets for Neuroprotection in Parkinson’s Disease

Yadav, A., Agarwal, S., Tiwari, S. K., & Chaturvedi, R. K. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140305224545 · Cited by 22

Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying

KONES, R. J. (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s12082 · Cited by 11

Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

Beal, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 529

Nonel approaches to correction of mitochondrial dysfunction and oxidative disorders in Parkinson’s disease

Gonchar, O. O., Im, M., Rozova, K. V., Bratus, L. V., & In, K. (2019) · Fìzìologìčnij žurnal · doi:10.15407/fz65.03.061 · Cited by 6